Cargando…
Comparison of the Therapeutic Effects of [(211)At]NaAt and [(131)I]NaI in an NIS-Expressing Thyroid Cancer Mouse Model
Astatine ((211)At) is an alpha-emitter with a better treatment efficacy against differentiated thyroid cancer compared with iodine ((131)I), a conventional beta-emitter. However, its therapeutic comparison has not been fully evaluated. In this study, we compared the therapeutic effect between [(211)...
Autores principales: | Watabe, Tadashi, Liu, Yuwei, Kaneda-Nakashima, Kazuko, Sato, Tatsuhiko, Shirakami, Yoshifumi, Ooe, Kazuhiro, Toyoshima, Atsushi, Shimosegawa, Eku, Wang, Yang, Haba, Hiromitsu, Nakano, Takashi, Shinohara, Atsushi, Hatazawa, Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409053/ https://www.ncbi.nlm.nih.gov/pubmed/36012698 http://dx.doi.org/10.3390/ijms23169434 |
Ejemplares similares
-
Preclinical Evaluation of Radiation-Induced Toxicity in Targeted Alpha Therapy Using [(211)At] NaAt in Mice: A Revisit()
por: Liu, Yuwei, et al.
Publicado: (2020) -
Extended single-dose toxicity study of [(211)At]NaAt in mice for the first-in-human clinical trial of targeted alpha therapy for differentiated thyroid cancer
por: Watabe, Tadashi, et al.
Publicado: (2021) -
Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019) -
Synthesis of [(211)At]4-astato-L-phenylalanine by dihydroxyboryl-astatine substitution reaction in aqueous solution
por: Shirakami, Yoshifumi, et al.
Publicado: (2021) -
Targeted alpha therapy using astatine ((211)At)-labeled phenylalanine: A preclinical study in glioma bearing mice
por: Watabe, Tadashi, et al.
Publicado: (2020)